Top

Published in:

Open Access 17-05-2023 | Original Article

Dysregulation of genes coding for proteins involved in metabolic processes in mucopolysaccharidoses, evidenced by a transcriptomic approach

Authors: Karolina Pierzynowska, Patrycja Deresz, Grzegorz Węgrzyn, Lidia Gaffke

Published in: Metabolic Brain Disease | Issue 6/2023

Abstract

Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases (LSD) caused by mutations in genes coding for enzymes responsible for degradation of glycosaminoglycans (GAGs). Most types of these severe disorders are characterized by neuronopathic phenotypes. Although lysosomal accumulation of GAGs is the primary metabolic defect in MPS, secondary alterations in biochemical processes are considerable and influence the course of the disease. Early hypothesis suggested that these secondary changes might be due to lysosomal storage-mediated impairment of activities of other enzymes, and subsequent accumulation of various compounds in cells. However, recent studies indicated that expression of hundreds of genes is changed in MPS cells. Therefore, we asked whether metabolic effects observed in MPS are caused primarily by GAG-mediated inhibition of specific biochemical reactions or appear as results of dysregulation of expression of genes coding for proteins involved in metabolic processes. Transcriptomic analyses of 11 types of MPS (using RNA isolated from patient-derived fibroblasts), performed in this study, showed that a battery of the above mentioned genes is dysregulated in MPS cells. Some biochemical pathways might be especially affected by changes in expression of many genes, including GAG metabolism and sphingolipid metabolism which is especially interesting as secondary accumulation of various sphingolipids is one of the best known additional (while significantly enhancing neuropathological effects) metabolic defects in MPS. We conclude that severe metabolic disturbances, observed in MPS cells, can partially arise from changes in the expression of many genes coding for proteins involved in metabolic processes.

Anheuser S, Breiden B, Sandhoff K (2019) Ganglioside GM2 catabolism is inhibited by storage compounds of mucopolysaccharidoses and by cationic amphiphilic drugs. Mol Genet Metabol 128:75–83. https://doi.org/10.1016/j.ymgme.2019.04.007CrossRef

Breiden B, Sandhoff K (2020) Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease. Int J Mol Sci 21:2566. https://doi.org/10.3390/ijms21072566CrossRefPubMedPubMedCentral

Brokowska J, Pierzynowska K, Gaffke L, Rintz E, Węgrzyn G (2021) Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses. Cell Biol Int 45:549–557. https://doi.org/10.1002/cbin.11332CrossRefPubMed

Brosseau C, Colas L, Magnan A, Brouard S (2018) CD9 tetraspanin: A new pathway for the regulation of inflammation? Front Immunol 9:2316. https://doi.org/10.3389/fimmu.2018.02316CrossRefPubMedPubMedCentral

Cyske Z, Gaffke L, Pierzynowska K, Węgrzyn G (2022) Complex changes in the efficiency of the expression of many genes in monogenic diseases, mucopolysaccharidoses, may arise from significant disturbances in the levels of factors involved in the gene expression regulation processes. Genes 13:593. https://doi.org/10.3390/genes13040593CrossRefPubMedPubMedCentral

Cyske Z, Gaffke L, Pierzynowska K, Węgrzyn G (2023) Expression of long noncoding RNAs in fibroblasts from mucopolysaccharidosis patients. Genes 14:271. https://doi.org/10.3390/genes14020271CrossRefPubMedPubMedCentral

David A, Chazeirat T, Saidi A, Lalmanach G, Lecaille F (2023) The interplay of glycosaminoglycans and cysteine cathepsins in mucopolysaccharidosis. Biomedicines 11:810. https://doi.org/10.3390/biomedicines11030810CrossRefPubMedPubMedCentral

Dorfman A, Matalon R (1976) The mucopolysaccharidoses (a review). Proc Natl Acad Sci U S A 73:630–637. https://doi.org/10.1073/pnas.73.2.630

Faye C, Moreau C, Chautard E, Jetne R, Fukai N, Ruggiero F, Humphries MJ, Olsen BR, Ricard-Blum S (2009) Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 284:22029–22040. https://doi.org/10.1074/jbc.M109.002840CrossRefPubMedPubMedCentral

Fecarotta S, Tarallo A, Damiano C, Minopoli N, Parenti G (2020) Pathogenesis of mucopolysaccharidoses, an update. Int J Mol Sci 21:2515. https://doi.org/10.3390/ijms21072515CrossRefPubMedPubMedCentral

Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ (2019) Clusterin in Alzheimer’s disease: Mechanisms, genetics, and lessons from other pathologies. Front Neurosci 13:164. https://doi.org/10.3389/fnins.2019.00164CrossRefPubMedPubMedCentral

Fu H, Meadows AS, Pineda RJ, Mohney RP, Stirdivant S, McCarty DM (2017) Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB. Metab Brain Dis 32:1403–1415. https://doi.org/10.1007/s11011-017-0009-1CrossRefPubMed

Gaffke L, Pierzynowska K, Podlacha M, Brokowska J, Węgrzyn G (2019) Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int. https://doi.org/10.1002/cbin.11275. (in Press)CrossRef

Gaffke L, Pierzynowska K, Podlacha M, Hoinkis D, Rintz E, Brokowska J, Cyske Z, Wegrzyn G (2020) Underestimated aspect of mucopolysaccharidosis pathogenesis: global changes in cellular processes revealed by transcriptomic studies. Int J Mol Sci 21:1204. https://doi.org/10.3390/ijms21041204CrossRefPubMedPubMedCentral

Heon-Roberts R, Nguyen A, Pshezhetsky AV (2020) Molecular bases of neurodegeneration and cognitive decline, the major burden of Sanfilippo disease. J Clin Med 9:E344. https://doi.org/10.3390/jcm9020344CrossRef

Kelly TE (1976) The mucopolysaccharidoses and mucolipidoses. Clin Orthop Relat Res 114:116–133

Kobayashi H (2019) Recent trends in mucopolysaccharidosis research. J Hum Genet 64:127–137. https://doi.org/10.1038/s10038-018-0534-8CrossRefPubMed

Kubaski F, de Oliveira PF, Michelin-Tirelli K, Graeff Burin M, Rojas-Málaga D, Brusius-Facchin AC, Leistner-Segal S, Giugliani R (2020) Diagnosis of Mucopolysaccharidoses. Diagnostics 10:172. https://doi.org/10.3390/diagnostics10030172CrossRefPubMedPubMedCentral

Leal AF, Benincore-Flórez E, Rintz E, Herreño-Pachón AM, Celik B, Ago Y, Alméciga-Díaz CJ, Tomatsu S (2022) Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets. Int J Mol Sci 24:477. https://doi.org/10.3390/ijms24010477CrossRefPubMedPubMedCentral

Mazzoccoli G, Tomanin R, Mazza T, D’Avanzo F, Salvalaio M, Rigon L, Zanetti A, Pazienza V, Francavilla M, Giuliani F, Vinciguerra M, Scarpa M (2013) Circadian transcriptome analysis in human fibroblasts from Hunter syndrome and impact of iduronate-2-sulfatase treatment. BMC Med Genomics 6:37. https://doi.org/10.1186/1755-8794-6-37CrossRefPubMedPubMedCentral

Miyazawa H, Aulehla A (2018) Revisiting the role of metabolism during development. Development 145:dev131110. https://doi.org/10.1242/dev.131110CrossRefPubMed

Muhlebach MS, Wooten W, Muenzer J (2011) Respiratory manifestations in mucopolysaccharidoses. Paedatr Resp Rev 12:133–138. https://doi.org/10.1016/j.prrv.2010.10.005CrossRef

Nagpal R, Goyal RB, Priyadarshini K, Kashyap S, Sharma M, Sinha R, Sharma N (2022) Mucopolysaccharidosis: A broad review. Indian J Ophthalmol 70:2249–2261. https://doi.org/10.4103/ijo.IJO_425_22CrossRefPubMedPubMedCentral

Parente MK, Rozen R, Cearley CN, Wolfe JH (2012) Dysregulation of gene expression in a lysosomal storage disease varies between brain regions implicating unexpected mechanisms of neuropathology. PloS One 7:e32419. https://doi.org/10.1371/journal.pone.0032419CrossRefPubMedPubMedCentral

Parente MK, Rozen R, Seeholzer SH, Wolfe JH (2016) Integrated analysis of proteome and transcriptome changes in the mucopolysaccharidosis type VII mouse hippocampus. Mol Genet Metabol 118:41–54. https://doi.org/10.1016/j.ymgme.2016.03.003CrossRef

Peck SH, Tobias JW, Shore EM, Malhotra NR, Haskins ME, Casal ML, Smith LJ (2019) Molecular profiling of failed endochondral ossification in mucopolysaccharidosis VII. Bone 128:115042. https://doi.org/10.1016/j.bone.2019.115042CrossRefPubMedPubMedCentral

Penon-Portmann M, Blair DR, Harmatz P (2023) Current and new therapies for mucopolysaccharidoses. Pediatr Neonatol 64(Suppl 1):S10–S17. https://doi.org/10.1016/j.pedneo.2022.10.001CrossRefPubMed

Pierzynowska K, Gaffke L, Podlacha M, Węgrzyn G (2020) Genetic base of behavioral disorders in mucopolysaccharidoses: transcriptomic studies. Int J Mol Sci 21:1156. https://doi.org/10.3390/ijms21031156CrossRefPubMedPubMedCentral

Pierzynowska K, Żabińska M, Gaffke L, Cyske Z, Węgrzyn G (2022) Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. Eur J Cell Biol 101:151232. https://doi.org/10.1016/j.ejcb.2022.151232CrossRefPubMed

Pierzynowska K, Gaffke L, Żabińska M, Cyske Z, Rintz E, Wiśniewska K, Podlacha M, Węgrzyn G (2023) Roles of the oxytocin receptor (OXTR) in human diseases. Int J Mol Sci 24:3887. https://doi.org/10.3390/ijms24043887CrossRefPubMedPubMedCentral

Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymańska A, Czartoryska B, Wegrzyn A, Wegrzyn G (2009) Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr 98:743–749. https://doi.org/10.1111/j.1651-2227.2008.01153.xCrossRefPubMed

Rintz E, Gaffke L, Podlacha M, Brokowska J, Cyske Z, Węgrzyn G, Pierzynowska K (2020) Transcriptomic changes related to cellular processes with particular emphasis on cell activation in lysosomal storage diseases from the group of mucopolysaccharidoses. Int J Mol Sci 21:3194. https://doi.org/10.3390/ijms21093194CrossRefPubMedPubMedCentral

Salvalaio M, D’Avanzo F, Rigon L, Zanetti A, D’Angelo M, Valle G, Scarpa M, Tomanin R (2017) Brain RNA-seq profiling of the mucopolysaccharidosis type II mouse model. Int J Mol Sci 18:1072. https://doi.org/10.3390/ijms18051072CrossRefPubMedPubMedCentral

Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pérez-González R, Pagonabarraga J, Kulisevsky J (2020) CLU rs11136000 promotes early cognitive decline in Parkinson’s disease. Mov Disord 35:508–513. https://doi.org/10.1002/mds.27949CrossRefPubMed

Saville JT, Fuller M (2020) Sphingolipid dyshomeostasis in the brain of the mouse model of mucopolysaccharidosis type IIIA. Mol Genet Metabol 129:111–116. https://doi.org/10.1016/j.ymgme.2019.08.008CrossRef

Stapleton M, Arunkumar N, Kubaski F, Mason RW, Tadao O, Tomatsu S (2018) Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metabol 125:4–17. https://doi.org/10.1016/j.ymgme.2018.01.003CrossRef

Swaroop M, Brooks MJ, Gieser L, Swaroop A, Zheng W (2018) Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. Human Mol Genet 27:3612–3626. https://doi.org/10.1093/hmg/ddy259CrossRef

Tebani A, Abily-Donval L, Schmitz-Afonso I, Héron B, Piraud M, Ausseil J, Zerimech F, Gonzalez B, Marret S, Afonso C, Bekri S (2018) Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis. J Transl Med 16:248. https://doi.org/10.1186/s12967-018-1625-1CrossRefPubMedPubMedCentral

Wilson MR, Zoubeidi A (2017) Clusterin as a therapeutic target. Expert Opin Therap Targets 21:201–213. https://doi.org/10.1080/14728222.2017.1267142CrossRef

Wiśniewska K, Wolski J, Gaffke L, Cyske Z, Pierzynowska K, Węgrzyn G (2022) Misdiagnosis in mucopolysaccharidoses. J Appl Genet 63:475–495. https://doi.org/10.1007/s13353-022-00703-1CrossRefPubMed

Yu J, Lee CY, Changou CA, Cedano-Prieto DM, Takada YK, Takada Y (2017) The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3. Biochem J 474:589–596. https://doi.org/10.1042/BCJ20160998CrossRefPubMed

Żabińska M, Gaffke L, Bielańska P, Podlacha M, Rintz E, Cyske Z, Węgrzyn G, Pierzynowska K (2023) Decreased levels of chaperones in mucopolysaccharidoses and their elevation as a putative auxiliary therapeutic approach. Pharmaceutics 15:704. https://doi.org/10.3390/pharmaceutics15020704CrossRefPubMedPubMedCentral

Zhang Y, Lv X, Chen L, Liu Y (2022) The role and function of CLU in cancer biology and therapy. Clin Exp Med. https://doi.org/10.1007/s10238-022-00885-2. (in Press)CrossRefPubMedPubMedCentral

Zhou J, Lin J, Leung WT, Wang L (2020) A basic understanding of mucopolysaccharidosis: Incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res 9:1–9. https://doi.org/10.5582/irdr.2020.01011CrossRefPubMedPubMedCentral

Title: Dysregulation of genes coding for proteins involved in metabolic processes in mucopolysaccharidoses, evidenced by a transcriptomic approach
Authors: Karolina Pierzynowska
Patrycja Deresz
Grzegorz Węgrzyn
Lidia Gaffke
Publication date: 17-05-2023
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 6/2023
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-023-01231-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dysregulation of genes coding for proteins involved in metabolic processes in mucopolysaccharidoses, evidenced by a transcriptomic approach

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2023

Retraction Note to: Changes in Cathepsin D and Beclin-1 mRNA and protein expression by the excitotoxin quinolinic acid in human astrocytes and neurons

Metformin attenuates sevoflurane-induced neurogenesis damage and cognitive impairment: involvement of the Nrf2/G6PD pathway

Correction to: Necrostatin-1 S mitigates type-2 diabetes-associated cognitive decrement and lipotoxicity-induced neuro-microglia changes through p-RIPK-RIPK3-p-MLKL axis

Stem cell therapy combined with luteolin alleviates experimental neuropathy

Exome sequence analysis of rare frequency variants in Late-Onset Alzheimer Disease

Complete Loss of Myelin protein zero (MPZ) in a patient with a late onset Charcot-Marie-Tooth (CMT)